



News Release

Puma Biotechnology Announces Publication of Abstracts for the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

- *Puma to host investor/analyst meeting and webcast on June 1* -

LOS ANGELES, Calif., May 13, 2015 – Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the release of four abstracts on its drug candidate PB272 (neratinib) that will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29 to June 2, 2015, in Chicago. Abstracts are available to the public online on the ASCO website: www.abstract.asco.org:

- Abstract #508: Breast Cancer—HER2/ER, Oral Abstract Session
- Abstract #610: Breast Cancer—HER2/ER, Poster Session
- Abstract #1085: Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy, Poster Session
- Abstract #1099: Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy, Poster Session

Puma will host an investor/analyst meeting in Chicago to discuss its clinical trial data presented at ASCO beginning at 7:00 p.m. CDT on Monday, June 1. The meeting will be webcast live and available for replay at www.pumabiotechnology.com/ir_events.html.

About Puma Biotechnology

Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2-positive breast cancer and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation.

Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.

Forward-Looking Statements:

This press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the risk factors disclosed in the periodic reports filed by the Company with the Securities and Exchange Commission from time to time. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.

Contacts:

Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500

info@pumabiotechnology.com

ir@pumabiotechnology.com

Robert Flamm or David Schull, Russo Partners, +1 212 845 4235

robert.flamm@russopartnersllc.com

david.schull@russopartnersllc.com

#####